Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Consensus Recommendations for Diagnosis and Treatment of Multiple Sclerosis: 2023 Revision of the Menactrims Guidelines Publisher Pubmed



Yamout B1 ; Aljumah M2 ; Sahraian MA3 ; Almalik Y4 ; Khaburi JA5 ; Shalaby N6 ; Aljarallah S7 ; Bohlega S8 ; Dahdaleh M9 ; Almahdawi A10 ; Khoury SJ11 ; Koussa S12 ; Slassi E13 ; Daoudi S14 Show All Authors
Authors
  1. Yamout B1
  2. Aljumah M2
  3. Sahraian MA3
  4. Almalik Y4
  5. Khaburi JA5
  6. Shalaby N6
  7. Aljarallah S7
  8. Bohlega S8
  9. Dahdaleh M9
  10. Almahdawi A10
  11. Khoury SJ11
  12. Koussa S12
  13. Slassi E13
  14. Daoudi S14
  15. Aref H15
  16. Mrabet S16
  17. Zeineddine M17
  18. Zakaria M18
  19. Inshasi J19
  20. Gouider R16
  21. Alroughani R20
Show Affiliations
Authors Affiliations
  1. 1. Neurology Institute and Multiple Sclerosis Center, Harley Street Medical Center, Abu Dhabi, United Arab Emirates
  2. 2. InterHealth hospital, Multiple Sclerosis Center, Riyadh, Saudi Arabia
  3. 3. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Division of Neurology, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, National Guard Health Affairs, King Abdulaziz Medical City, Riyadh, Saudi Arabia
  5. 5. Department of Neurology, The Royal Hospital, Oman
  6. 6. Neurology Department, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
  7. 7. King Saud University, Saudi Arabia
  8. 8. King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
  9. 9. Al Khalidi Hospital, Amman, Jordan
  10. 10. Consultant Neurologist, Neurology Unit, Baghdad Teaching Hospital, Medical City Complex, Iraq
  11. 11. Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon
  12. 12. Multiple Sclerosis Center, Geitaoui Lebanese University Hospital, Beirut, Lebanon
  13. 13. Hopital Cheikh Khalifa Ibn Zaid, Casablanca, Morocco
  14. 14. Hospital Center Nedir Mohamed, Faculty of Medicine, University Mouloud Mammeri Tizi-Ouzou, Algeria
  15. 15. Neurology Department, Ain Shams University, Cairo, Egypt
  16. 16. Department of Neurology, CIC, Razi Universitary Hospital, University of Tunis El Manar, Tunis, Tunisia
  17. 17. Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS), Beirut, Lebanon
  18. 18. Ain Shams University, Cairo, Egypt
  19. 19. Department of Neurology, Rashid Hospital and Dubai Medical College, Dubai Health Authority, Dubai, United Arab Emirates
  20. 20. Amiri Hospital, Arabian Gulf Street, Sharq, Kuwait

Source: Multiple Sclerosis and Related Disorders Published:2024


Abstract

With evolving diagnostic criteria and the advent of new oral and parenteral therapies for Multiple Sclerosis (MS), most current diagnostic and treatment algorithms need revision and updating. The diagnosis of MS relies on incorporating clinical and paraclinical findings to prove dissemination in space and time and exclude alternative diseases that can explain the findings at hand. The differential diagnostic workup should be guided by clinical and laboratory red flags to avoid unnecessary tests. Appropriate selection of MS therapies is critical to maximize patient benefit. The current guidelines review the current diagnostic criteria for MS and the scientific evidence supporting treatment of acute relapses, radiologically isolated syndrome, clinically isolated syndrome, relapsing remitting MS, progressive MS, pediatric cases and pregnant women. The purpose of these guidelines is to provide practical recommendations and algorithms for the diagnosis and treatment of MS based on current scientific evidence and clinical experience. © 2024 Elsevier B.V.
Related Docs
View other Related Docs
1. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: 2019 Revisions to the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2020)
2. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (Menactrims), Current Medical Research and Opinion (2015)
3. A Comprehensive Review on the Treatment Approaches of Multiple Sclerosis: Currently and in the Future, Inflammation Research (2019)
4. Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management, Neuroinflammation (2018)
5. Efficacy of Disease Modifying Therapies in Progressive Ms and How Immune Senescence May Explain Their Failure, Frontiers in Neurology (2022)
6. Monoclonal Antibodies in Multiple Sclerosis Treatment, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
7. Intervening to Reduce the Risk of Future Disability From Multiple Sclerosis: Are We There Yet?, International Journal of Neuroscience (2017)
8. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? a Narrative Review, Neurology and Therapy (2020)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (60)
Abdolreaza Naser Moghadasi (19)
Other Related Docs
9. Immunopathogenesis of Multiple Sclerosis: Molecular and Cellular Mechanisms and New Immunotherapeutic Approaches, Immunopharmacology and Immunotoxicology (2024)
10. The Efficacy and Safety of Oral Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2020)
11. Current and Future Trends in Multiple Sclerosis Management: Near East Perspective, Multiple Sclerosis and Related Disorders (2023)
12. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Neurology and Therapy (2022)
13. Evaluating the Efficacy and Safety of Zytuxtm (Rituximab, Aryogen Pharmed) in Iranian Multiple Sclerosis Patients: An Observational Study, Multiple Sclerosis and Related Disorders (2019)
14. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
15. Efficacy and Safety of Rituximab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2023)
16. B Cells in Multiple Sclerosis Therapy—A Comprehensive Review, Acta Neurologica Scandinavica (2018)
17. Early Predictors of Conversion to Secondary Progressive Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2021)
18. Multiple Sclerosis Epidemiology in Middle East and North Africa: A Systematic Review and Meta-Analysis, Neuroepidemiology (2015)
19. Recent Advances in Mesenchymal Stem Cell Therapy for Multiple Sclerosis: Clinical Applications and Challenges, Frontiers in Cell and Developmental Biology (2025)
20. Cost-Effectiveness of Alemtuzumab and Natalizumab for Relapsing-Remitting Multiple Sclerosis Treatment in Iran: Decision Analysis Based on an Indirect Comparison, Journal of Medical Economics (2019)
21. Primary Progressive Multiple Sclerosis in Iran: A Consensus Recommendation for Diagnosis and Management, Multiple Sclerosis and Related Disorders (2018)
22. The Prevalence of Cancer in Patients With Multiple Sclerosis (Ms) Who Received Rituximab: A Systematic Review and Meta-Analysis; [La Prevalencia De Cancer En Pacientes Con Esclerosis Multiple (Em) Que Recibieron Rituximab: Una Revision Sistematica Y Meta-Analisis], Neurologia (2025)
23. Comparing Infusion-Related Reactions of the First Full Dose (600 Mg) Biosimilar Ocrelizumab Administration With the Standard Divided Protocol in Multiple Sclerosis Patients: A Randomized Controlled Trial Study, Acta Neurologica Belgica (2024)
24. Post Marketing New Adverse Effects of Oral Therapies in Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2022)
25. Multiple Sclerosis: Therapeutic Applications of Advancing Drug Delivery Systems, Biomedicine and Pharmacotherapy (2017)
26. Unraveling the Impact of 27-Hydroxycholesterol in Autoimmune Diseases: Exploring Promising Therapeutic Approaches, Pathology Research and Practice (2023)
27. Anti-Jc Virus Antibody Sera Positivity and Index Value Among Patients With Multiple Sclerosis May Be Correlated With Age, Sex, and Area of Residence, Journal of NeuroVirology (2018)
28. Effect of Pregnancy and Exclusive Breastfeeding on Multiple Sclerosis Relapse Rate and Degree of Disability Within Two Years After Delivery, Clinical Neurology and Neurosurgery (2020)
29. Comparable Efficacy and Safety of Teriflunomide Versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis, Neurology Research International (2021)
30. Introduction to the Neuroimmunology of Multiple Sclerosis, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
31. The Epidemiologic Trend of Multiple Sclerosis in Razavi Khorasan Province, Iran in Fifteen-Year Period, Multiple Sclerosis and Related Disorders (2025)
32. Efficacy and Safety of Natalizumab Extended Interval Dosing, Multiple Sclerosis and Related Disorders (2018)
33. Autoimmune Diseases, Clinical Immunology (2022)
34. Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review, Neuroepidemiology (2016)
35. Prevalence and Incidence of Multiple Sclerosis in Tehran, Iran, Iranian Journal of Public Health (2017)
36. Pregnancy Outcome in Patients With Multiple Sclerosis Treated With Rituximab: A Case-Series Study, Multiple Sclerosis and Related Disorders (2021)
37. The Effect of Probiotics on Immune Responses and Their Therapeutic Application: A New Treatment Option for Multiple Sclerosis, Biomedicine and Pharmacotherapy (2023)
38. Differential Diagnosis of Suspected Multiple Sclerosis: Global Health Considerations, The Lancet Neurology (2024)
39. Association Between Disease-Modifying Therapies and Adverse Clinical Outcomes in Multiple Sclerosis Patients With Covid-19 Infection, Multiple Sclerosis and Related Disorders (2022)
40. Incidence of Cancer in Patients With Multiple Sclerosis (Ms) Who Were Treated With Fingolimod: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
41. Characterization of Cd4+ and Cd8+ T Cell Subsets and Interferon Regulatory Factor 4 (Irf4) in Ms Patients Treated With Fingolimod (Fty-720); a Follow-Up Study, Iranian Journal of Allergy# Asthma and Immunology (2018)
42. Prevalence of Anti-Jc Virus Antibody Seropositivity in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis, Intervirology (2020)
43. The Role of the Cerebellum in Multiple Sclerosis, Cerebellum (2015)
44. Potential Role of Regulatory B Cells in Immunological Diseases, Immunology Letters (2019)
45. Effects of Vaccination on Covid-19 Infection Symptoms in Multiple Sclerosis Patients, eNeurologicalSci (2024)
46. Multiple Sclerosis Pathogenesis: Missing Pieces of an Old Puzzle, Reviews in the Neurosciences (2019)
47. Clinical and Radiological Activity After Extended Interval and Standard Interval Dosing of Ocrelizumab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Neurological Sciences (2025)
48. Pharmacokinetics and Bioequivalence Studies of Teriflunomide in Healthy Iranian Volunteers, Clinical Pharmacology in Drug Development (2020)
49. A Comparison of Pediatric and Adult Neuromyelitis Optica Spectrum Disorders: A Review of Clinical Manifestation, Diagnosis, and Treatment, Journal of the Neurological Sciences (2018)
50. Cladribine Tablets Are a Cost-Effective Strategy in High-Disease Activity Relapsing Multiple Sclerosis Patients in Iran, Current Journal of Neurology (2021)